Diligence memo · auto-generated · as of July 2, 2026
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Scorpius Holdings, Inc. operates in Biotechnology, based in MORRISVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Scorpius Holdings, Inc. has raised $24M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $13M on 2024-12-06.
Most recent recorded round closed around 2025-02-12.
Valuation (modeled)modeled
Provath models Scorpius Holdings, Inc. at approximately $3.9M (range $1.1M–$7.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.25× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 31 months.
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 70% of Biotechnology peers (4293 compared).
Modeled value ranks above 8% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
21 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.